8-K/AOther EventsExhibits & Filings

VERTEX PHARMACEUTICALS INC / MA 8-K/A Report, Corporate Update (Sep 10, 2004)

Filed September 10, 2004For Securities:VRTX

Summary

This filing is an amendment to a previous 8-K report, specifically addressing an agreement between Vertex Pharmaceuticals Incorporated (VRTX) and Mitsubishi Pharma Corporation. The amendment is primarily to refile the License, Development and Commercialization Agreement with revised redactions based on the SEC's review of Vertex's confidential treatment request. For investors, this means the details of the agreement, previously redacted, are now presented with updated confidential information removed. While the core terms of the partnership with Mitsubishi are now more accessible, the specific financial or strategic details that Vertex deemed confidential remain protected. Investors should review the updated Exhibit 99.2 to understand the revised level of disclosure regarding this important collaboration.

Key Highlights

  • 1Amendment to a previous Form 8-K filing by Vertex Pharmaceuticals Incorporated.
  • 2The amendment relates to the License, Development and Commercialization Agreement with Mitsubishi Pharma Corporation, dated June 11, 2004.
  • 3The purpose of the amendment is to refile the agreement with revised redactions after SEC review of a confidential treatment request.
  • 4Exhibit 99.2 now contains the agreement with updated confidential information redacted.
  • 5The event date reported is June 11, 2004, the effective date of the agreement.
  • 6The filing was made on September 9, 2004, with the earliest event date being June 11, 2004.

Frequently Asked Questions

This filing is an amendment to a previous 8-K report. Vertex Pharmaceuticals is refiling the License, Development and Commercialization Agreement with Mitsubishi Pharma Corporation because the SEC reviewed their confidential treatment request, and Vertex has now provided the agreement with revised redactions.

The agreement with Mitsubishi Pharma Corporation (Exhibit 99.2) is now available with updated redactions. While some specific confidential information may still be omitted, the revised redactions offer a clearer view of the agreement's terms than previously provided.

The amendment's primary purpose is to adjust the redactions based on the SEC's review, not necessarily to disclose new strategic or financial details that were previously kept confidential. The level of detail available will depend on what Vertex still deems confidential and has redacted accordingly.

June 11, 2004, is the effective date of the License, Development and Commercialization Agreement between Vertex Pharmaceuticals and Mitsubishi Pharma Corporation, which is the subject of this filing.